secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001193125-25-129531
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC
----------------------------------------------------------------------

- $125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.
- Pro forma cash into 2H 2027 funds through first ORIC-944 Phase 3 registrational trial primary endpoint.
- ORIC-944 + AR inhibitor achieved 59% PSA50 (10/17), 47% confirmed PSA50, and 24% PSA90 (4/17) in heavily pretreated mCRPC.
- Safety mostly Grade 1/2 GI events (diarrhea 53%, one Grade 3); no Grade 4/5 treatment-related AEs.
- Phase 1b dose optimization in 2H 2025; first global Phase 3 registrational trial expected to start in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525129531/0001193125-25-129531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525129531/d911818d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-129531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer